{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:31:46Z","timestamp":1786365106899,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005635","name":"Calouste Gulbenkian Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO3-AI173522"],"award-info":[{"award-number":["RO3-AI173522"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1-AI076423"],"award-info":[{"award-number":["RO1-AI076423"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["RO1 AR061569"],"award-info":[{"award-number":["RO1 AR061569"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["RO1 ES017627"],"award-info":[{"award-number":["RO1 ES017627"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002193","name":"Lupus Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010842","name":"Temple University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010842","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017759","name":"Childhood Arthritis and Rheumatology Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017759","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.intimp.2024.112692","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T14:06:13Z","timestamp":1722261973000},"page":"112692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon \u03b1-accelerated murine lupus"],"prefix":"10.1016","volume":"140","author":[{"given":"Paul M.","family":"Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Chain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Costa-Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112692_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus Nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2024.112692_b0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on Lupus Nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2024.112692_b0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0049-0172(96)80027-8","article-title":"Outcome of silent lupus nephritis","volume":"26","author":"Gonzalez-Crespo","year":"1996","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.112692_b0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/0961203306070002","article-title":"Further description of early clinically silent lupus nephritis","volume":"15","author":"Zabaleta-Lanz","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2024.112692_b0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2024.112692_b0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3904\/kjim.2017.383","article-title":"New insights into the role of renal resident cells in the pathogenesis of lupus nephritis","volume":"33","author":"Kwok","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.intimp.2024.112692_b0035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semarthrit.2019.06.002","article-title":"Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies","volume":"49","author":"Leatherwood","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.112692_b0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/jir.2011.0045","article-title":"Type I interferon and systemic lupus erythematosus","volume":"31","author":"Elkon","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.intimp.2024.112692_b0045","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2024.112692_b0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.112692_b0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/08916930310001625952","article-title":"Microarray analysis of interferon-regulated genes in SLE","volume":"36","author":"Crow","year":"2003","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2024.112692_b0060","doi-asserted-by":"crossref","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"Ronnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.intimp.2024.112692_b0065","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.gene.6364421","article-title":"Genomic view of IFN-alpha response in pre-autoimmune NZB\/W and MRL\/lpr mice","volume":"8","author":"Lu","year":"2007","journal-title":"Genes Immun."},{"key":"10.1016\/j.intimp.2024.112692_b0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4049\/jimmunol.1101686","article-title":"Myeloid dendritic cells from B6.NZM Sle1\/Sle2\/Sle3 lupus-prone mice express an IFN signature that precedes disease onset","volume":"189","author":"Sriram","year":"2012","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.intimp.2024.112692_b0075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaut.2009.10.001","article-title":"Emerging roles of TLR7 and TLR9 in murine SLE","volume":"33","author":"Santiago-Raber","year":"2009","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2024.112692_b0080","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.4049\/jimmunol.0803872","article-title":"Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease","volume":"183","author":"Agrawal","year":"2009","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.intimp.2024.112692_b0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0896-8411(02)00109-9","article-title":"Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice","volume":"20","author":"Braun","year":"2003","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2024.112692_b0090","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.4049\/jimmunol.1203525","article-title":"Exacerbated Autoimmunity in the Absence of TLR9 in MRL.Faslpr Mice Depends on Ifnar1","volume":"190","author":"Nickerson","year":"2013","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.intimp.2024.112692_b0095","article-title":"Partial Protection From Lupus-Like Disease by B-Cell Specific Type I Interferon Receptor Deficiency","volume":"11","author":"Keller","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112692_b0100","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.4049\/jimmunol.174.5.2499","article-title":"IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB\/c mice","volume":"174","author":"Mathian","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112692_b0105","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1002\/eji.200837925","article-title":"Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice","volume":"38","author":"Fairhurst","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2024.112692_b0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.30087","article-title":"Interferon-\u03b1 accelerates murine systemic lupus erythematosus in a T cell-dependent manner","volume":"63","author":"Liu","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.112692_b0115","first-page":"306","article-title":"IFN\u03b1 Inducible Models of Murine SLE","volume":"4","author":"Liu","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112692_b0120","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/art.39219","article-title":"The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis","volume":"67","author":"Costa-Reis","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2024.112692_b0125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2024.112692_b0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2024.112692_b0135","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1146\/annurev-pharmtox-070115-095427","article-title":"Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System","volume":"56","author":"Forrester","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2024.112692_b0140","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00030.2015","article-title":"Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease","volume":"96","author":"Chen","year":"2016","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.intimp.2024.112692_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000719","article-title":"Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis","volume":"9","author":"Costa-Reis","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.intimp.2024.112692_b0150","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/ndt\/9.7.764","article-title":"Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury","volume":"9","author":"Nakopoulou","year":"1993","journal-title":"Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.intimp.2024.112692_b0155","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1172\/JCI114359","article-title":"Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure","volume":"84","author":"Humes","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.112692_b0160","first-page":"43","article-title":"Epidermal growth factor accelerates renal repair in mercuric chloride nephrotoxicity","volume":"259","author":"Coimbra","year":"1990","journal-title":"Am. J. Phys. Anthropol."},{"key":"10.1016\/j.intimp.2024.112692_b0165","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0090-4295(97)00101-5","article-title":"Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction","volume":"49","author":"Kennedy","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.intimp.2024.112692_b0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ki.2012.43","article-title":"Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury","volume":"82","author":"Chen","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2024.112692_b0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1681\/ASN.2011070645","article-title":"EGFR signaling promotes TGF\u03b2-dependent renal fibrosis","volume":"23","author":"Chen","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.intimp.2024.112692_b0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1172\/JCI8315","article-title":"Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury","volume":"106","author":"Terzi","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.112692_b0185","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/nm.2491","article-title":"Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis","volume":"17","author":"Boll\u00e9e","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.112692_b0190","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ki.2012.435","article-title":"Role of epidermal growth factor receptor in acute and chronic kidney injury","volume":"83","author":"Tang","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2024.112692_b0195","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nrneph.2014.184","article-title":"Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease","volume":"10","author":"Kok","year":"2014","journal-title":"Nature Reviews Nephrology"},{"key":"10.1016\/j.intimp.2024.112692_b0200","doi-asserted-by":"crossref","first-page":"e013053","DOI":"10.1136\/bmjopen-2016-013053","article-title":"Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Xu","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.intimp.2024.112692_b0205","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2024.112692_b0210","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2407-10-188","article-title":"Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model","volume":"11","author":"Diaz","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2024.112692_b0215","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1634\/theoncologist.12-7-756","article-title":"Lapatinib-associated toxicity and practical management recommendations","volume":"12","author":"Moy","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2024.112692_b0220","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112692_b0225","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas","volume":"23","author":"Burris","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112692_b0230","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.111.040949","article-title":"Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity","volume":"40","author":"Castellino","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.intimp.2024.112692_b0235","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","article-title":"Cardiotoxicity of novel HER2-targeted therapies","volume":"29","author":"Sendur","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.intimp.2024.112692_b0240","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.2007.14.5029","article-title":"Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial","volume":"26","author":"Ravaud","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112692_b0245","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.4049\/jimmunol.0803565","article-title":"Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation","volume":"182","author":"Jog","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112692_b0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10928-012-9295-8","article-title":"Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans","volume":"40","author":"Hudachek","year":"2013","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.intimp.2024.112692_b0255","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4049\/jimmunol.171.1.489","article-title":"Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB\/W F1 mice by a mechanism downstream of renal immune complex deposition","volume":"171","author":"Schiffer","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112692_b0260","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12026-015-8693-6","article-title":"Molecular studies of lupus nephritis kidneys","volume":"63","author":"Davidson","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.intimp.2024.112692_b0265","doi-asserted-by":"crossref","unstructured":"Cohen, P., and M. Maldonado. 2003. Animal models for SLE. Current protocols in immunology \/ edited by John E. Coligan ... [et al.] Chapter 15.","DOI":"10.1002\/0471142735.im1520s52"},{"key":"10.1016\/j.intimp.2024.112692_b0270","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.immuni.2015.06.002","article-title":"Amyloid-DNA Composites of Bacterial Biofilms Stimulate Autoimmunity","volume":"42","author":"Gallo","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.112692_b0275","doi-asserted-by":"crossref","unstructured":"Seavey, M., L. Lu, and K. Stump. 2011. Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery. Current protocols in pharmacology \/ editorial board, S.J. Enna (editor-in-chief) ... [et al.] Chapter 5.","DOI":"10.1002\/0471141755.ph0560s53"},{"key":"10.1016\/j.intimp.2024.112692_b0280","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.1523-1755.2002.00230.x","article-title":"Modulation of renal disease in MRL\/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase","volume":"61","author":"Reilly","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2024.112692_b0285","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-61779-367-7_13","article-title":"Glomerular epithelial and mesangial cell culture and characterization","volume":"806","author":"Wilson","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.intimp.2024.112692_b0290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrrheum.2009.240","article-title":"Lupus nephritis: lessons from murine models","volume":"6","author":"Davidson","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2024.112692_b0295","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2024.112692_b0300","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.112692_b0305","doi-asserted-by":"crossref","first-page":"F622","DOI":"10.1152\/ajprenal.00134.2011","article-title":"Galectin-7 modulates the length of the primary cilia and wound repair in polarized kidney epithelial cells","volume":"301","author":"Rondanino","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.intimp.2024.112692_b0310","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1038\/s41598-020-68480-7","article-title":"Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1\/2, STAT3, p53 and apoptotic pathways","volume":"10","author":"Awad","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.112692_b0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.yexcr.2016.06.009","article-title":"Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney","volume":"346","author":"Sheng","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.intimp.2024.112692_b0320","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","article-title":"Emerging Functions of Amphiregulin in Orchestrating Immunity, Inflammation, and Tissue Repair","volume":"42","author":"Zaiss","year":"2015","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2024.112692_b0325","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2024.112692_b0330","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","article-title":"HLA-DQA1* 02: 01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer","volume":"29","author":"Spraggs","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112692_b0335","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","article-title":"A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer","volume":"19","author":"Burstein","year":"2008","journal-title":"Ann. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692401213X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692401213X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:59:29Z","timestamp":1786363169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692401213X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":67,"alternative-id":["S156757692401213X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112692","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon \u03b1-accelerated murine lupus","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112692"}}